Invokana Demonstrates Cardiovascular Risk Reductions for Type-2 Diabetes Patients

A new analysis was announced by Johnson & Johnson JNJ from a large CANVAS outcomes program on its type II diabetes drug, Invokana (SGLT2 inhibitor), which has showed a reduced risk of cardiovascular outcomes in patients with or without a history of CV disease and also achieved risk reductions for hospitalization due to heart failure (HHF) and renal outcomes in each of the primary and secondary prevention groups. The late-breaking results were presented at the annual meeting of the American Heart Association Scientific Sessions in California on November 13 and published in Circulation.

This new analysis of CANVAS showed two high-CV-risk type 2 diabetes patient groups: showed a reduction in the risk of the composite renal endpoint in both patient groups with a history of CV disease (secondary prevention) and with only risk factors for CV disease (primary prevention). As per the analysis, Invokana demonstrated a reduction in the risk of hospitalization due to heart failure (HHF) in both patient groups. No new adverse events were observed for other CV and renal outcomes across the primary and secondary prevention groups.

As previously reported by the investors that in June, the company reported data from the CANVAS program, Invokana was successful in reducing the risks of cardiovascular in type II diabetes patients, who have established cardiovascular disease or are at a risk for CV disease, nonfatal myocardial infarction (MI) and nonfatal stroke. The overall adverse event profile for Invokana, it reduced major adverse CV events by 14% compared with placebo. However, the study also showed that the Invokana may increase your risk of lower-limb amputations.

Safety Information About Invokana:

Invokana is used along with diet and exercise in adults with type 2 diabetes to control high blood sugar in people with type 2 diabetes. Controls high blood sugar which helps to prevent kidney damage. This drug works by increasing the removal of sugar by your kidneys.

Side Effects: Amputations. Invokana may increase your risk of lower-limb amputations.

Signs and symptoms of low blood sugar may include Frequent urination, unusual dry mouth, dizziness, lightheadedness, irritability, hunger, fast heartbeat, sweating, shaking, or feeling jittery.

Serious allergic reaction. If any symptoms of a serious allergic reaction, stop taking Invokana

Broken Bones (fractures): Bone fractures have been seen in patients by taking Invokanaokana

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2 × 3 =